This article is more than 5 years old. Information may no longer be current.

Pfizer to appeal court ruling invalidating Celebrex reissue patent

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Pfizer has announced that the US District Court for the Eastern District of Virginia gave a summary judgment invalidating the reissue patent for treating osteoarthritis and other approved conditions with celecoxib.

Celecoxib is the active ingredient in Pfizer’s Celebrex, which also is indicated for treating rheumatoid arthritis and ankylosing spondylitis.

Pfizer said in a press release that it disagrees with the ruling and “will pursue all available remedies, including an immediate appeal of the court’s decision.”

Pfizer had brought action against generic manufacturers Teva Pharmaceuticals USA; Mylan Pharmaceuticals; Watson Laboratories; Lupin Pharmaceuticals, USA; Apotex Corp.; and Apotex Inc. in a trial that was scheduled to begin March 19 for infringement of the reissue patent, according to the release.

The companies previously had filed an abbreviated new drug application with the FDA for approval to market a generic version of celecoxib in the US beginning on May 30, when Pfizer’s basic patent for Celebrex expires, which is 18 months before the Dec. 2, 2015 expiration of the reissue patent, the release stated.